TFS
CRDF icon

Thoroughbred Financial Services’s Cardiff Oncology CRDF Stock Holding History

Thoroughbred Financial Services’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,614
Closed -$61K – 589
2025
Q1 		$61K Hold
19,614
– – ﹤0.01% 661
2024
Q4 		$85K Buy
19,614
+5,970
+44% +$18.7K 0.01% 673
2024
Q3 		$36K Sell
13,644
-38,731
-74% -$91.5K ﹤0.01% 651
2024
Q2 		$116K Buy
+52,375
New +$197K 0.01% 616

Other funds holding CRDF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thoroughbred Financial Services's CRDF Position: Q2 2025 in Review

Thoroughbred Financial Services sold out of Cardiff Oncology (CRDF) in Q2 2025, closing a stake of 19,614 shares — an estimated $61K sold.

Thoroughbred Financial Services first reported a position in CRDF in Q2 2024 and held it in 4 quarters. The position peaked at $116K in Q2 2024. 114 funds tracked by Wall St. Rank hold CRDF as of Q2 2025.

  • Thoroughbred Financial Services reported no remaining Cardiff Oncology position as of Q2 2025 after selling out during the quarter.
  • Thoroughbred Financial Services sold 19,614 Cardiff Oncology shares in Q2 2025, an estimated $61K.
  • Thoroughbred Financial Services first reported a position in Cardiff Oncology in Q2 2024 and held it in 4 quarters.
  • Thoroughbred Financial Services's Cardiff Oncology position peaked at $116K in Q2 2024.
  • 114 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2025.

Based on Thoroughbred Financial Services's 13F filing for Q2 2025, filed 8 Aug 2025.